Clinical Trial Update: Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) [Phase 3]

View source ↗

Summary

Phase 3 trial update (ODYSSEY JAPAN) evaluating the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia or high cardio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia Heterozygous
• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2016-01-29